Instem plc Appointment of Joint Broker (9618X)

TIDMINS

RNS Number : 9618X

Instem plc

11 January 2022

Instem plc

("Instem", the "Group" or the "Company")

Appointment of Stifel as Joint Broker

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces the appointment of Stifel Nicolaus Europe Limited ("Stifel") as the Company's joint broker with immediate effect.

Stifel will work alongside Instem's existing broker, Singer Capital Markets, as the Company focuses on further increasing liquidity and engagement with US-based institutional investors.

For further information, please contact:

 
 Instem plc                           Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated 
  Adviser & Joint Broker)             +44 (0) 20 7496 3000 
 Peter Steel 
  Alex Bond 
  Rachel Hayes 
 
 Stifel Nicolaus Europe Limited 
  (Joint Broker)                      +44 (0)20 7710 7600 
 Ben Maddison 
 Alex Price 
 
 Walbrook Financial PR                +44 (0) 20 7933 8780 
 Tom Cooper                           instem@walbrookpr.com 
 Nick Rome 
 Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPGZGMMFGFGZZM

(END) Dow Jones Newswires

January 11, 2022 02:00 ET (07:00 GMT)

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024